trending Market Intelligence /marketintelligence/en/news-insights/trending/x6u1jeutxscqvu1unuskca2 content esgSubNav
In This List

DexCom loses patent challenge against WaveForm

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


DexCom loses patent challenge against WaveForm

The U.S. Patent and Trademark Office's Patent Trial and Appeal Board upheld two patents challenged by San Diego's DexCom Inc.

The patents, held by WaveForm Technologies Inc., cover aspects of its continuous glucose monitoring, or CGM, system. WaveForm sued DexCom in 2016, saying that Dexcom's G4 and G5 CGM products infringe on three of its patents. The board has yet to make a decision on the third patent.

WaveForm's 2016 lawsuit was filed in the U.S. District Court for the District of Oregon.

DexCom is a provider of continuous glucose monitoring technology, used to help patients manage diabetes.